Next step in rapid diagnostics for infectious diseases

Source: Flinders University

News • Vortex fluidic device

Next step in rapid diagnostics for infectious diseases

The speedy, high-tech method of inexpensive, accurate and high-throughput protein biomarker assay testing is being touted as a much-needed development in point-of-care (PoC) testing.

The new method—using the revolutionary vortex fluidic device (VFD) developed by Flinders University—can be readily scaled up to test hundreds and "potentially thousands" of proteins in one assay in less than five minutes, says senior researcher University of California, Irvine Professor Gregory Weiss, who is a U.S. leader in VFD experiments and applications.

"Most importantly, the data produced can be accurately read with a cell phone camera—immediately addressing the gap between development and implementation of biomarker-based precision medicine," he says.

While many costly tests can take upwards of 48–72 hours, on-the-spot tests such as this can lead to accurate diagnosis and early commencement of important drug treatments and reduction of wrong medications.

Photo
Source: Flinders University

An accessible universal solution to offer rapid personalized mobile testing for infectious diseases—or diagnosis and delivery of targeted treatments for other diseases even in remote areas—has so far been out of reach.

"The extreme disparity between technologically lagging and advanced settings directly impacts disease mortality and morbidity, particularly for infectious diseases," says Flinders University researcher Dr. Xuan Luo, a co-author in a new article on the novel test.

In the assessment published in international chemistry journal Angewandte Chemie, the new method, labeled VFD-accelerated immunoblot assay (VAIA), was compared and found superior to other PoC biomarker-based tests currently in use.

Not only was the processing faster and accurate, it sliced up to 70% off the cost of sometimes toxic reagents. While many immunoblot assays are used to detect certain diseases, many are not highly sensitive and complex to use—even for technicians in a laboratory or clinical setting.

In contrast the VAIA was found to improve conventional processing time from hours to less than five minutes, using three major immunoassay formats with purified proteins and biofluids.

Source: Flinders University

23.06.2022

Read all latest stories

Related articles

Photo

News • ECCMID 2015

Curetis launches next-generation pneumonia application

Curetis AG, a developer of next-level molecular diagnostic solutions, announced the successful completion of the clinical and analytical CE performance evaluation of its next-generation Unyvero P55…

Photo

News • Multiplex immunoassay

Dengue Fever: hope for low-cost diagnostics

Accurate home testing could be used for a wider range of illnesses, as new research shows the capability of smartphone-powered tests for Dengue Fever.

Photo

News • Infectious disease

Sensor technology could detect Dengue fever earlier

Researchers from the University of Bath are developing a new tool for detecting the presence of Dengue fever early on, helping prevent people from suffering potential life-threatening complications.

Related products

Associates of Cape Cod – Fungitell STAT Assay

Identification/Susceptibility

Associates of Cape Cod – Fungitell STAT Assay

Associates of Cape Cod Europe GmbH
Hologic – Novodiag System

Automation & sample processing

Hologic – Novodiag System

Hologic, Inc.
Lifotronic - FA-160 Immunofluorescence Analyzer

Immunoassays

Lifotronic - FA-160 Immunofluorescence Analyzer

Lifotronic Technology Co., Ltd
Lifotronic  SARS-CoV-2 Antibody Detection Kit

Immunoassays

Lifotronic SARS-CoV-2 Antibody Detection Kit

Lifotronic Technology Co., Ltd
Lifotronic – SARS-CoV-2 Antigen

Immunoassays

Lifotronic – SARS-CoV-2 Antigen

Lifotronic Technology Co., Ltd
Nova Biomedical – StatStrip Glucose/Ketone*

Blood Glucose

Nova Biomedical – StatStrip Glucose/Ketone*

Nova Biomedical Corporation
Subscribe to Newsletter